Pfizer Inspra submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer submits sNDA in April for use of its selective aldosterone blocker Inspra (eplerenone) for congestive heart failure. The sNDA is based on the EPHESUS trial, which showed a mortality reduction for post-MI patients receiving eplerenone (1Pharmaceutical Approvals Monthly March 1, p. 23). The firm said April 22 that Inspra would not be launched until the CHF indication is cleared; the antihypertensive was first approved Sept. 27, 2002, for hypertensio
You may also be interested in...
Inspra Efficacy In Blacks Insufficient For Superiority Claim, Priority Review
A superiority claim for Pharmacia’s anti-hypertensive Inspra for increased efficacy in black patients would require replicated efficacy in large placebo-controlled trials, FDA said in review documents.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.